Shasun Pharmaceuticals has soared 10% to Rs 113 on NSE, extending its previous day’s 11% rally, after the company said that it has a robust sales plan and growth strategy in place for the next three years, based on a wide range of pipeline and marketed products.
On business update of its UK subsidiary SPSL, the company said that the declining performance of Incevik, key product of one of its customer would not have significant impact on the performance for the current year.
“In December, the company secured a major contract for 2013-14 worth over GBP 5.3 million for a big pharmaceutical client. The production for this will start from February 2013,” Shasun Pharma said in a statement.
The stock opened at Rs 104 and has seen a combined 2.21 million shares changing hands on the counter so far against an average 0.73 million shares that were traded daily in past two weeks.
